In recent years, the life sciences and pharmaceutical industry has undergone profound changes. New forms of therapy, such as cell and gene therapies, advances in immuno-oncology, and the rapid development of GLP-1 drugs for obesity and diabetes have reshaped the competitive landscape. At the same time, artificial intelligence, data-driven research, and digital platform models are driving the pace of innovation forward at a rapid pace.
Parallel to this, pressure is mounting: patent expiries, regulatory requirements, price discussions, and risks in supply chains are forcing companies to realign their strategies. In this article, we highlight the top-grossing pharmaceutical and life sciences companies in 2025, identify growth segments, regional dynamics, and M&A trends, and venture a look ahead to the coming years. This overview is ideal for making informed investment and personnel decisions.
The global pharmaceutical market remains one of the largest submarkets in the healthcare sector. The global market volume is estimated at around US$1.6 trillion for 2025. Analysts expect stable growth in the long term until 2030, with a compound annual growth rate (CAGR) of around 4 to 6%.
The main drivers of this growth are:
The biopharmaceuticals and specialty therapeutics sector is growing particularly strongly and increasingly dominating the traditional small molecule markets.
The “Emerging Biopharma” technologies segment includes highly innovative therapeutic approaches such as:
Since 2023, a particularly significant growth driver has been the boom in GLP-1-based drugs for the treatment of diabetes and obesity. This trend has not only catapulted the sales of Novo Nordisk and Eli Lilly to new heights, but is also influencing the strategic planning of the product pipelines of many large pharmaceutical companies.
In 2025, the global pharmaceutical market will continue to show significant regional differences.
North America will remain the dominant market, accounting for around 40% of global sales. This is due to high healthcare spending, an innovation-friendly capital market environment, and a strong research and start-up landscape.
Europe continues to hold a significant share of 25 to 30 percent. The most important pharmaceutical locations include Germany, France, the United Kingdom, and Switzerland. At the same time, price regulation and cost pressure are creating a challenging market environment.
Asia-Pacific is developing into the most dynamic growth region. China and India are massively expanding their production capacities and their research and clinical infrastructure. China in particular is increasingly positioning itself as a center of innovation for biotechnology.
Latin America, the Middle East, and Africa remain smaller markets, but are gaining in importance due to growing healthcare spending and infrastructure programs.
The following companies will be among the world's largest pharmaceutical and life sciences groups in 2025. For better comparability, revenues have been converted to USD (rounded, based on average exchange rates in 2025).
Johnson & Johnson: $94.2 billion
The world's largest healthcare company maintains its position as the clear market leader. In addition to pharmaceuticals, medtech continues to play an important role in the company's portfolio.
Roche: approx. USD 67.7 billion
The Swiss group remains one of the most important players in the fields of oncology and diagnostics. It is considered a global innovation leader in the field of personalized medicine.
Merck & Co. (MSD): $65.0 billion
MSD is and remains one of the dominant players in the field of immuno-oncology and vaccines. The company benefits greatly from its leading portfolio in the field of cancer medicine.
Pfizer: $62.6 billion
Despite post-pandemic normalization, Pfizer remains a revenue giant and is investing heavily in expanding its pipeline and new platforms.
AbbVie: $61.2 billion
Following the Humira era, AbbVie has successfully diversified and continues to have a strong presence in immunology, neurology, and specialty pharmaceuticals.
AstraZeneca: approx. $58–59 billion
AstraZeneca continues to record strong growth thanks to its strategies in the areas of oncology and rare diseases and is one of the most dynamic top players.
Novartis: USD 54.5 billion
Novartis has a clear strategic focus on innovative medicines and is continuously expanding its pipeline in the areas of oncology and immunology.
Sanofi: approx. USD 47.1 billion
Dupixent and the vaccine division are driving Sanofi's development into an immunology and specialty pharmaceuticals group.
Novo Nordisk: approx. USD 46.4 billion
Novo Nordisk has been one of the biggest winners in recent years. GLP-1 therapies are driving sales to new heights and changing the global market structure.
Eli Lilly: approx. USD 44–45 billion
Similar to Novo Nordisk, Lilly is benefiting from the metabolic boom and will be one of the fastest-growing pharmaceutical companies in 2025.
Bristol Myers Squibb (BMS): approx. USD 45–46 billion
BMS remains a heavyweight in oncology and immunology and is driving the renewal of its pipeline through partnerships and acquisitions.
GSK: approx. USD 41.5 billion
GSK remains strong in the areas of vaccines and specialty pharma and is pursuing a clear focus strategy.
Amgen: approx. USD 28–29 billion
Amgen remains one of the leading biotech companies and is investing heavily in the fields of oncology and inflammatory medicine.
Takeda: approx. USD 29–30 billion
Takeda remains Japan's largest pharmaceutical company and has a particularly strong presence in the fields of gastroenterology and rare diseases.
Bayer (pharmaceuticals segment): approx. USD 19–20 billion
Bayer remains relevant as a pharmaceutical company, but is caught between the conflicting priorities of being a diversified group and undergoing structural realignment.
This list makes it clear that even in 2025, a few mega-corporations will dominate the global market, while individual specialist segments such as obesity and immunotherapy will create a new growth order.
Germany remains one of the most important locations for the pharmaceutical industry in Europe, both in terms of research and production.
Boehringer Ingelheim is the largest German pharmaceutical company in the narrow sense and will achieve sales of around EUR 23 billion (approximately USD 25 billion) in 2025. The company has a strong presence in the areas of human pharmaceuticals, veterinary medicine, and innovative therapy platforms.
Bayer and Merck KGaA are also among the most important German life sciences companies. However, neither company operates exclusively in the pharmaceutical sector, but is highly diversified.
Germany is also a central location for international corporations, CDMOs, and research partners. They all strengthen the ecosystem in areas such as biologics production, clinical trials, and diagnostics.
In addition to the sales giants, there are numerous specialized companies that shape the innovative dynamics of the industry.
These include in particular:
It is precisely these specialized players who are often the drivers of innovation, M&A activity, and growth in the early stages of the value chain.
Innovation is and remains the key growth driver in the pharmaceutical industry.
Artificial intelligence is changing the entire logic of research and development: from target identification and molecular design to the planning of clinical trials. Generative AI can significantly shorten development times and reduce costs. This is strategically crucial in an industry with extremely high R&D expenditure.
Biologics are increasingly dominating the most important revenue drivers. Cell and gene therapies are expanding the possibilities, particularly for rare diseases and in oncology. At the same time, the requirements for production, logistics, and approval in these areas are increasing.
GLP-1 therapies triggered the largest structural shift in sales in decades in 2025. With their blockbuster drugs, Novo Nordisk and Eli Lilly are changing not only the pharmaceutical industry, but the entire healthcare ecosystem.
Decentralized studies, digital patient recruitment, real-world evidence, and data-based approval models are rapidly gaining importance and will bring about lasting change in clinical development.
Consolidation will remain a dominant theme in 2025. Large pharmaceutical companies are using acquisitions to ...
The strategy is increasingly shifting from “big deals at any price” to targeted acquisitions that focus on late-stage development and platform technologies.
The industry remains highly regulated. At the same time, requirements are increasing.
While the US remains the most innovative and profitable market, cost pressures and reimbursement policies in Europe are key strategic factors.
The long-term outlook remains robust. Analysts expect the global pharmaceutical market to grow to over USD 2 trillion by 2034. The following areas are developing particularly dynamically:
The industry will not only grow, but also undergo structural change. The focus will shift away from traditional blockbuster logic and toward platform strategies, data-driven development, and highly specialized therapy portfolios.
BESTMINDS supports companies in the IT / media, medical technology, life sciences / pharma, and healthcare industries in filling top and key positions. Thanks to our in-depth industry knowledge and our extensive talent network, we find the executives and experts who will make your innovation and growth goals a reality.
Contact us without obligation using our contact form. We are passionate about meeting your challenges.
